CAZZANIGA, MARINA ELENA

CAZZANIGA, MARINA ELENA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 128 (tempo di esecuzione: 0.04 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 01 - Articolo su rivista 2024 Cazzaniga M. E.Zambelli A. +
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions(Front. Oncol., (2023), 13, (1249160), 10.3389/fonc.2023.1249160) 99 - Altro 2024 Cazzaniga M. +
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection 01 - Articolo su rivista 2024 Foti G.Citerio G.Pesci A.Valsecchi M. G.Cazzaniga M.Bellani G.Bruno R.Biondi A.Bettini L. R.Beretta I. +
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer 01 - Articolo su rivista 2024 Cazzaniga M. E. +
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 01 - Articolo su rivista 2023 Zambelli A.Cazzaniga M.Antonazzo I. C.Mantovani L. G.Cortesi P. A. +
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 01 - Articolo su rivista 2023 Cazzaniga, Marina EBonfanti, Paolo +
A second update on mapping the human genetic architecture of COVID-19 01 - Articolo su rivista 2023 Invernizzi, PietroGerussi, AlessioBiondi, AndreaBellani, GiacomoBellelli, GiuseppeCiterio, GiuseppeFoti, GiuseppeBettini, Laura RacheleValsecchi, Maria G.Cazzaniga, MarinaFaverio, PaolaBonfanti, Paolo +
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 01 - Articolo su rivista 2023 Cazzaniga M. E. +
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 01 - Articolo su rivista 2023 Cordani N.Bianchi T.Cortinovis D. L.Cazzaniga M. E.Lissoni A. A.Landoni F. +
Aromatase inhibitors: the journey from the state of the art to clinical open questions 01 - Articolo su rivista 2023 Cazzaniga M. +
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 02 - Intervento a convegno 2023 Gotuzzo, ICazzaniga, MDe Bernardi, ECicchiello, FCordani, NCerrito, MTurolla, ELandoni, CCrivellaro, CVirdone, LMonaco, LGuerra, L +
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 01 - Articolo su rivista 2023 Cordani N.Paglia G.Meanti R.Cerrito M. G.Villa C.Mauri M.Mologni L.Torsello A.Cazzaniga M. E. +
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study 01 - Articolo su rivista 2023 Cazzaniga M. +
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients 01 - Articolo su rivista 2023 Cazzaniga M. E. +
GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial 01 - Articolo su rivista 2023 Bonfanti P.Cazzaniga M. E. +
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project 01 - Articolo su rivista 2023 Cazzaniga M. E.Luppi F. +
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 02 - Intervento a convegno 2023 Nicoletta CordaniLuca MologniRocco PiazzaCamillo Di BellaMaria Grazia CerritoMatteo VillaGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 01 - Articolo su rivista 2023 Foti G.Bellani G.Citerio G.Valsecchi M. G.Cazzaniga M.Biondi A.Bettini L. R. +
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 01 - Articolo su rivista 2023 Zambelli A.Cazzaniga M. E. +